EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Extrapancreatic effect of somatostatin infusion to increase glucose clearance



Extrapancreatic effect of somatostatin infusion to increase glucose clearance



American Journal of Physiology 247(3 Pt 1): E370-E379



Constant intraportal insulin, coupled with variable intraportal glucagon, was used in the attempt to reestablish basal metabolic conditions in dogs during somatostatin (SRIF) infusion (0.8 micrograms X min-1 X kg-1). SRIF alone lowered glucose (G), insulin (I), and glucagon (GN) (G: 90 +/- 5 to 69 +/- 1 mg/dl; I: 18 +/- 4 to 4 +/- 1 microU/ml; GN: 257 +/- 52 to 168 +/- 40 pg/ml; P less than 0.05 or better). Hormone replacement. Hypoglycemia persisted (G at steady state, SS, 60-150 min): 12 +/- 3 mg/dl below basal; P = 0.006) despite intraportal insulin replacement (200 microU X min-1 X kg-1; insulin at basal: 14 +/- 1; at SS: 14 +/- 2 microU/ml; P greater than 0.9) and glucagon overreplacement (basal: 341 +/- 42; SS: 486 +/- 80 pg/ml; P less than 0.05). Glucose clearance was increased 65% above basal (P less than 0.0001). Insulin underreplacement. With a lower intraportal insulin infusion rate (50 microU X min-1 X kg-1), insulin fell from basal (10 +/- 2 microU/ml) to 4 +/- 1 microU/ml during steady state (P = 0.03). Glucose and glucose clearance were normalized to basal values (G: 85 +/- 3 mg/dl, P = 0.3; clearance: 5.7 +/- 0.5 ml X min-1 X kg-1; P = 0.2) with full glucagon replacement (basal: 281 +/- 120; SS: 264 +/- 80 pg/ml; P greater than 0.9). Thus, during constant SRIF infusion, normoglycemia was reattained when insulin was underreplaced via the portal vein. The failure to reattain euglycemia with normoinsulinemia was due to a SRIF-induced increase in extrahepatic glucose clearance. Insulin replacement and growth hormone (GH) infusion. GH (15 ng X min-1 X kg-1) partially reversed the hypoglycemia during SRIF, with full insulin replacement. The SRIF-induced increase in glucose clearance may be partially mediated by a decrease in GH.

(PDF 0-2 workdays service: $29.90)

Accession: 001364988

Download citation: RISBibTeXText

PMID: 6148014



Related references

Effect of simultaneous infusion of a somatostatin analog insulin and glucose on serum triglycerides and blood glucose levels in man. Endocrinologia Japonica 32(2): 241-248, 1985

Glucose conservation by the kidney and effect of systemic glucose infusion on inulin clearance in female goats. American Journal of Veterinary Research 51(4): 587-590, 1990

Failure of somatostatin to decrease blood glucose by suppression of extrapancreatic glucagon in severely diabetic depancreatized dogs. Endocrinologia Japonica 25(6): 529-532, 1978

Effect of verapamil on glucose response to glucagon during intravenous infusion of somatostatin. Hormone and Metabolic Research 12(10): 554-555, 1980

Effect of somatostatin infusion on plasma immuno reactive glucagon and glucose in pancreatectomized man. Clinical Research: 130a, 1977

Effect of somatostatin and a glucagon-specific analog on glucose homeostasis during arginine infusion. Metabolism: Clinical and Experimental 27(9): 1095-1100, 1978

Effect of glucose-insulin-potassium infusion on thallium myocardial clearance. Circulation 68(1): 203-209, 1983

Glucose infusion potentiates the acute insulin response to nonglucose stimuli during the infusion of somatostatin. Endocrinology 105(5): 1215-1220, 1979

The effect of glucose insulin potassium infusion on thallium myo cardial clearance rate. American Heart Association Monograph (82): IV-242, 1981

Prolonged hyperglycaemia during infusion of glucose and somatostatin impairs pancreatic A- and B-cell responses to decrements in plasma glucose in normal man: evidence for induction of altered sensitivity to glucose. Diabetologia 28(2): 63-69, 1985

Kinetics of gastric inhibitory poly peptide and its effect on glucose turnover during somatostatin infusion in dogs. Scandinavian Journal of Gastroenterology Supplement 13(49): 150, 1978

Effect of 24-hour somatostatin infusion on glucose homeostasis and on the levels of somatomedin A and pancreatic and thyroid hormones in man. Acta Medica Scandinavica 206(6): 441-445, 1979

Effect of 24 hour somatostatin infusion on glucose homeostasis and levels of somatomedin a and pancreatic and thyroid hormones in man. Acta Medica Scandinavica 206(6): 441-446, 1979